Takeshi Nabe
Overview
Explore the profile of Takeshi Nabe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
100
Citations
596
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Involvement of CCR5 on interstitial macrophages in the development of lung fibrosis in severe asthma
Matsuda M, Shimora H, Nagatani Y, Nishikawa K, Takamori I, Haguchi T, et al.
Int Immunopharmacol
. 2024 May;
135:112331.
PMID: 38795597
CCR5 may be involved in the pathogenesis of asthma; however, the underlying mechanisms remain unclear. In comparison with a mild asthma model, subepithelial fibrosis was more severe and CCR5 gene...
3.
Shimora H, Matsuda M, Nakayama Y, Maeyama H, Tanioka R, Tanaka Y, et al.
Immunology
. 2024 May;
172(4):653-668.
PMID: 38786548
The mechanisms underlying the development of steroid resistance in asthma remain unclear. To establish whether as well as the mechanisms by which the activation of Janus kinases (JAKs) is involved...
4.
Ohya Y, Ogiso Y, Matsuda M, Sakae H, Nishida K, Miki Y, et al.
Cells
. 2024 Mar;
13(5.
PMID: 38474369
Regulated necrosis, termed necroptosis, represents a potential therapeutic target for refractory cancer. Ceramide nanoliposomes (CNLs), considered potential chemotherapeutic agents, induce necroptosis by targeting the activating protein mixed lineage kinase domain-like...
5.
Shimora H, Matsuda M, Takemoto N, Nomura M, Hamaguchi J, Terakawa R, et al.
Biol Pharm Bull
. 2024 Jan;
47(1):227-231.
PMID: 38246609
Between 5 and 10% of asthma patients do not respond to glucocorticoid therapy. Experimental animal models are indispensable for investigating the pathogenesis of steroid-resistant asthma; however, the majority of murine...
6.
Hayashi K, Saeki M, Miura K, Yamasaki N, Matsuda M, Shimora H, et al.
Allergy
. 2023 Jun;
78(10):2780-2783.
PMID: 37382229
No abstract available.
7.
Sakae H, Ogiso Y, Matsuda M, Shimora H, Deering T, Fox T, et al.
Cells
. 2023 Feb;
12(4).
PMID: 36831258
Ceramides are an emerging class of anti-inflammatory lipids, and nanoscale ceramide-delivery systems are potential therapeutic strategies for inflammatory diseases. This study investigated the therapeutic effects of ceramide nanoliposomes (CNL) on...
8.
Matsuda M, Shimizu S, Kitatani K, Nabe T
Pathogens
. 2022 Nov;
11(11).
PMID: 36422624
Allergen immunotherapy (AIT), such as subcutaneous immunotherapy (SCIT), is a treatment targeting the causes of allergic diseases. The roles of extracellular vesicles (EVs), bilayer lipid membrane blebs released from all...
9.
Nabe T
Nihon Yakurigaku Zasshi
. 2022 Sep;
157(5):299-304.
PMID: 36047139
There is a certain population of intractable asthma patients, who can not be controlled by corticosteroid therapy. It has been suggested that 5-10% of asthma patients have been suffered from...
10.
Matsuda M, Terada T, Kitatani K, Kawata R, Nabe T
Front Allergy
. 2022 Aug;
3:981126.
PMID: 35991310
Allergen-specific immunotherapy (AIT) is the only causative treatment for allergic diseases by modification of the immune response to allergens. A key feature of AIT is to induce immunotolerance to allergens...